Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN11 | Q06124 | 20/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.51 |
| ▸ | EGFR | P00533 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23425209 | 0.92 | PTPN11 (0.52) | PTPN11KCNH2EGFR | |
| SCHEMBL30295949 | 0.91 | PTPN11 (0.62) | PTPN11KCNH2EGFR | |
| SCHEMBL19785582 | 0.91 | PTPN11 (0.62) | PTPN11KCNH2EGFR | |
| SCHEMBL21154182 | 0.87 | PTPN11 (0.61) | PTPN11KCNH2EGFR | |
| SCHEMBL24233684 | 0.86 | PTPN11 (0.47) | PTPN11KCNH2EGFR | |
| SCHEMBL22694136 | 0.85 | PTPN11 (0.49) | PTPN11KCNH2EGFR | |
| SCHEMBL22694114 | 0.85 | PTPN11 (0.49) | PTPN11KCNH2EGFR | |
| SCHEMBL22694153 | 0.82 | PTPN11 (0.49) | PTPN11KCNH2EGFR | |
| SCHEMBL22694138 | 0.82 | PTPN11 (0.63) | PTPN11KCNH2EGFR | |
| SCHEMBL23425210 | 0.82 | PTPN11 (0.41) | PTPN11KCNH2EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200368238-A1 | SHP2 INHIBITOR COMPOSITIONS AND METHODS FOR TREATING CANCER | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2020-11-26 | — | — | US | disclosed |
| US-20190210977-A1 | 2,5-DISUBSTITUTED 3-METHYL PYRAZINES AND 2,5,6-TRISUBSTITUTED 3-METHYL PYRAZINES AS ALLOSTERIC SHP2 INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2019-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190210977-A1 | 2,5-DISUBSTITUTED 3-METHYL PYRAZINES AND 2,5,6-TRISUBSTITUTED 3-METHYL PYRAZINES AS ALLOSTERIC SHP2 INHIBITORS | PTPN5, PTPN2, PTPN22 | PTPN11 12/4885KCNH2 3436/4885EGFR 980/4885 |
| US-20200368238-A1 | SHP2 INHIBITOR COMPOSITIONS AND METHODS FOR TREATING CANCER | DUSP3, PTPRCAP, PTPN1 | PTPN11 32/4885KCNH2 4786/4885EGFR 499/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.